High tumor mutational burden (TMB) is associated with immunotherapy, and several genes related to high TMB, including ARID1A, RNF43, BRAF, and KM2B in microsatellite instability (MSI) tumors, may also be used for the treatment of MSS patients (48). Here, BRAF is linked to neoplasm.